<DOC>
	<DOCNO>NCT02159326</DOCNO>
	<brief_summary>Physicians might concern Adempas may metabolic interaction oral contraceptive ( OC ) could decrease contraceptive efficacy OC . The information regard lack potential pharmacokinetic interaction communicate ; need re-assurance data interaction Adempas OCs . A drug-drug interaction study riociguat OC Microgynon least vulnerable population purpose , i.e . healthy postmenopausal woman , consider adequate inform safe use Adempas OCs .</brief_summary>
	<brief_title>Microgynon Riociguat Drug Interaction Study Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<criteria>Healthy female subject Nonsmokers least 3 month screen Age : 52 65 year ( inclusive ) first screen examination Ethnicity : white Body mass index ( BMI ) &gt; =20 &lt; =32 kg/m2 Postmenopausal state , define Medical history , applicable ( natural menopause least 12 month first study drug administration hormone analyse serum Age &lt; 60 year : folliclestimulating hormone ( FSH ) &gt; 40 IU/L plasma Age &lt; 60 year : estradiol ( E2 ) &lt; 20 ng/L ( &lt; 73 pmol/L ) plasma History coronary artery disease , Symptomatic postural hypotension , History bronchial asthma , know hypersensitivity study , relevant disease within 4 week study drug administration , Presence history venous arterial thrombotic / thromboembolic event cerebrovascular accident , high risk venous arterial thrombosis , Use systemic topical medicine substance oppose study objective , smoking , use sex hormone form Clinically relevant finding ECG , systolic blood pressure 110 145 mmHg , heart rate 50 95 beat per minute Clinically relevant finding gynecological examination , Participation another clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>52 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>